FindTrial
Sign In

Comparative effect of two unani drugs in the treatment of Primary Dysmenorrhea-A randomized clinical Study.

Comparative effect of Zarawand and Qust in Primary Dysmenorrhea-A randomized clinical Study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/030900
Enrollment
60
Registered
2021-02-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

Intervention1: Group A:Zarawande mudaharaj(Aristolochia rotunda Linn).: Powder of zarawande mudaharaj as per standard preparation.6,16 Dosage and duration: 2gm twice daily with 5ml of honey from 1st

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: painful menstruation with regular cycles

Exclusion criteria

Exclusion criteria: Contraceptives. Pelvic pathology. Systemic illnesses & Malignancy. Lactation.

Design outcomes

Primary

MeasureTime frame
Primary outcome measure: change in subjective parameter like Painful menstruation LBA,nausea, vomiting,diarrhea, giddiness and headache. Timepoint: asess after 3 cycles—

Secondary

MeasureTime frame
Secondary outcome measure: change in objective parameter VAS, VMS, SF-12. Timepoint: assess after 3 cycles—

Countries

India

Contacts

Public ContactProf Wajeeha Begum

National Institute of Unani Medicine

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026